Circulating hsa-miR-29c-3p and VEGF-A levels predict the response to FOLFIRI plus aflibercept in elderly metastatic colorectal cancer patients
Por:
Toledano-Fonseca, M, Cano-Osuna, MT, Elez, E, Soto-Alsar, J, Paáez, D, Fernández-Montes, A, Graña, B, Salud, A, Yubero, A, Macías, I, Quintero, G, López-López, C, Fernández-Rodríguez, T, García-Ortiz, MV, Sastre, J, García-Alfonso, P, Rodríguez-Ariza, A, Aranda, E
Publicada:
17 ene 2026
Ahead of Print:
1 ago 2025
Resumen:
BackgroundMetastatic colorectal cancer (mCRC) patients who progress on oxaliplatin-based chemotherapy benefit from second-line treatment with FOLFIRI plus the antiangiogenic drug aflibercept. However, the absence of validated biomarkers for antiangiogenic therapies remains a challenge. In this context, we previously reported that combining plasma VEGF-A levels, a circulating microRNA profile, and patient clinical characteristics predicts outcomes in FOLFIRI plus aflibercept treatment. In the present study, we now report biomarkers of response to FOLFIRI plus aflibercept in elderly mCRC patients who progressed after first-line oxaliplatin-based chemotherapy.MethodsThe study included 154 mCRC patients over 70 years of age enrolled in the clinical phase II trial AFEMA. Plasma samples were obtained before FOLFIRI plus aflibercept treatment, and circulating levels of VEGF-A and 13 miRNAs were analysed.ResultsThe levels of VEGF-A and five of these 13 miRNAs (miR-193-3b, miR-432-5p, miR-29c-3p, miR-93-5p, miR-30a-3p) enabled the stratification of patients based on progression-free survival and time-to-treatment failure. Specifically, combining miR-29c-3p with VEGF-A improved prognostic accuracy.ConclusionOur study underscores the value of integrating miR-29c-3p analysis with VEGF-A as a biomarker strategy to advance the management of elderly mCRC patients receiving FOLFIRI plus aflibercept, improving outcome predictions and enabling more personalised therapeutic strategies.
Filiaciones:
Toledano-Fonseca, M:
Univ Cordoba, Reina Sofia Univ Hosp, Maimonides Biomed Res Inst Cordoba IMIBIC, Med Oncol Dept, Cordoba, Spain
Canc Network Biomed Res Ctr CIBERONC, Madrid, Spain
Cano-Osuna, MT:
Univ Cordoba, Reina Sofia Univ Hosp, Maimonides Biomed Res Inst Cordoba IMIBIC, Med Oncol Dept, Cordoba, Spain
Canc Network Biomed Res Ctr CIBERONC, Madrid, Spain
Elez, E:
Univ Autonoma Barcelona, Vall dHebron Barcelona Hosp Campus, Vall dHebron Inst Oncol VHIO, Med Oncol Dept,CIBERONC, Barcelona, Spain
Soto-Alsar, J:
Univ Complutense, Gregorio Maranon Gen Univ Hosp, Med Oncol Dept, Inst Invest Sanitaria Gregorio Maranon IiSGM, Madrid, Spain
Paáez, D:
Hosp Santa Creu & Sant Pau, Med Oncol Dept, CIBERER, Barcelona, Spain
Fernández-Montes, A:
Complexo Hosp Univ Ourense, Med Oncol Dept, Orense, Spain
Graña, B:
Pontevedra Univ Hosp SERGAS, Galicia Sur Hlth Res Inst IISGS, Med Oncol Dept, Pontevedra, Spain
Salud, A:
Hosp Univ Arnau Vilanova Lleida, Med Oncol Dept, Lleida, Spain
Yubero, A:
Univ Hosp Lozano Blesa, Inst Hlth Res Aragon IIS Aragon, Med Oncol Dept, Zaragoza, Spain
Macías, I:
Hosp Parc Tauli Sabadell, Med Oncol Dept, Barcelona, Spain
Quintero, G:
Hosp Lucus Augusti, Med Oncol Dept, Lugo, Spain
López-López, C:
Hosp Univ Marques Valdecilla, Med Oncol Dept, IDIVAL, UNICAN, Santander, Spain
Fernández-Rodríguez, T:
Hosp Univ Son Llatzer, Med Oncol Dept, Mallorca, Spain
García-Ortiz, MV:
Univ Cordoba, Reina Sofia Univ Hosp, Maimonides Biomed Res Inst Cordoba IMIBIC, Med Oncol Dept, Cordoba, Spain
Canc Network Biomed Res Ctr CIBERONC, Madrid, Spain
Sastre, J:
Univ Complutense, Hosp Clin San Carlos, Inst Invest Hosp Clin San Carlos IdISSC, Med Oncol Dept, Madrid, Spain
García-Alfonso, P:
Univ Complutense, Gregorio Maranon Gen Univ Hosp, Med Oncol Dept, Inst Invest Sanitaria Gregorio Maranon IiSGM, Madrid, Spain
Rodríguez-Ariza, A:
Univ Cordoba, Reina Sofia Univ Hosp, Maimonides Biomed Res Inst Cordoba IMIBIC, Med Oncol Dept, Cordoba, Spain
Canc Network Biomed Res Ctr CIBERONC, Madrid, Spain
Aranda, E:
Univ Cordoba, Reina Sofia Univ Hosp, Maimonides Biomed Res Inst Cordoba IMIBIC, Med Oncol Dept, Cordoba, Spain
Canc Network Biomed Res Ctr CIBERONC, Madrid, Spain
Green Submitted, hybrid
|